Provided by Tiger Fintech (Singapore) Pte. Ltd.

Axsome Therapeutics

103.25
+0.25000.24%
Volume:482.43K
Turnover:49.98M
Market Cap:5.04B
PE:-17.22
High:104.35
Open:103.74
Low:102.65
Close:103.00
Loading ...

Is Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock in 2025?

Insider Monkey
·
14 Mar

AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals

Zacks
·
06 Mar

TD Cowen Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

TIPRANKS
·
06 Mar

Axsome Therapeutics Price Target Maintained With a $200.00/Share by HC Wainwright & Co.

Dow Jones
·
06 Mar

Axsome Therapeutics: Strategic Developments and Market Exclusivity Drive Buy Rating

TIPRANKS
·
06 Mar

Axsome Therapeutics management to meet with Piper Sandler

TIPRANKS
·
06 Mar

Axsome Therapeutics Resolves Sunosi Patent Case With Hikma

MT Newswires Live
·
05 Mar

Axsome Therapeutics Inc - Hikma to Sell Generic Sunosi From Sept 2040 IF Pediatric Exclusivity Granted

THOMSON REUTERS
·
05 Mar

Axsome Therapeutics Settles Sunosi® (Solriamfetol) Patent Litigation With Hikma Pharmaceuticals USA

THOMSON REUTERS
·
05 Mar

Axsome Therapeutics Inc - Co and Hikma to Submit Settlement Agreement for FTC and DOJ Review

THOMSON REUTERS
·
05 Mar

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

GlobeNewswire
·
05 Mar

Axsome Therapeutics (AXSM) Gets a Buy from Mizuho Securities

TIPRANKS
·
05 Mar

Axsome Therapeutics: Promising Regulatory Progress and Market Potential Justify Buy Rating

TIPRANKS
·
04 Mar

Axsome Therapeutics’ AXS-05: Promising Regulatory Progress and Strategic Positioning for Market Success

TIPRANKS
·
04 Mar

Axsome Therapeutics Receives FDA Indication in Support of Alzheimer's Drug Submission

MT Newswires Live
·
04 Mar

Axsome Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
03 Mar

Axsome Therapeutics Announces FDA Pre-Nda Meeting Minutes for Axs-05 in Alzheimer’s Disease Agitation Supporting Nda Submission

THOMSON REUTERS
·
03 Mar

Axsome Therapeutics Inc - to Submit Snda for Axs-05 in Q3 2025

THOMSON REUTERS
·
03 Mar

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

GlobeNewswire
·
03 Mar

Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025

Insider Monkey
·
02 Mar